Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1606 of 5804
-
Umbilical cord wrap may help men recover faster after prostate cancer surgery
Symptom relief OngoingThis study aims at evaluating if placement of CLARIX® CORD 1K during robotic prostatectomy decreases the time to achieve complete erectile and urinary function after the surgery. As part of the study, the patient will be asked to answer various questions after the surgery regardi…
Phase: PHASE2, PHASE3 • Sponsor: Hackensack Meridian Health • Aim: Symptom relief
Last updated Jun 27, 2026 12:37 UTC
-
Drug duo targets tough tumors in early trial
Disease control OngoingThis phase II trial studies how well olaparib and ceralasertib (AZD6738) work in treating patients with IDH mutant cholangiocarcinoma or solid tumors. Cancer is caused by changes (mutations) to genes that control the way cells function. Laboratory studies have shown that olaparib…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Pee power: urine test could spot kidney cancer without needles
Diagnosis Recruiting nowClear cell renal cell carcinoma is diagnosed by imaging, sometimes associated with biopsy. This diagnosis is expensive, invasive and sometimes late. The development of a simple biological test for diagnosis is essential. Exosomes are 30 to 150 nm membrane vesicles secreted into t…
Sponsor: Centre Hospitalier Universitaire de Saint Etienne • Aim: Diagnosis
Last updated Jun 27, 2026 12:29 UTC
-
New anesthesia bundle cuts deadly lung complications in half?
Disease control CompletedPostoperative pulmonary complications (PPCs) are a major cause of morbidity and mortality in surgical patients. National estimates suggest 1,062,000 PPCs per year, with 46,200 deaths, and 4.8 million additional days of hospitalization. The objective of the study is to develop and…
Phase: NA • Sponsor: Columbia University • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New targeted pill shows promise for japanese blood cancer patients
Disease control CompletedThis is a Phase 1/2 study of zanubrutinib in Japanese participants with mature B-cell malignancies. This study intends to assess the use of zanubrutinib as an investigational agent to develop new treatment options for Japanese participants with B-cell malignancies. No formal hyp…
Phase: PHASE1, PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Engineered immune cells take aim at stubborn leukemia
Disease control TerminatedThis dose-escalating phase I trial assesses for the first time the safety, the side effects and the harmlessness, as well as the therapeutical benefit of the new study drug UniCAR02-T-CD123 in patients with hematologic and lymphatic malignancies positive for CD123 marker. The Uni…
Phase: PHASE1 • Sponsor: AvenCell Europe GmbH • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New resilience program aims to help african americans take control of diabetes
Disease control OngoingAfrican Americans are twice as likely to have type 2 diabetes as non-Hispanic Whites and are less likely to engage in effective diabetes self-management. There is a critical need for intensive lifestyle interventions that address the distress inherent in having the disease and th…
Phase: NA • Sponsor: University of Texas at Austin • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New dissolving film could calm agitation in schizophrenia without needles
Symptom relief CompletedThis is a definitive study to support the safety and efficacy evaluation of BXCL501 for the acute treatment of agitation in schizophrenia. The BXCL501-301 study is designed to characterize the efficacy, safety and tolerability of BXCL501 (sublingual film formulation of DEX, HCl) …
Phase: PHASE3 • Sponsor: BioXcel Therapeutics Inc • Aim: Symptom relief
Last updated Jun 27, 2026 13:02 UTC
-
Gene therapy for rare brain disease tracked over years
Disease control OngoingThis is a long-term safety and efficacy study in subjects with CLN6 Batten disease who previously received a single intrathecal administration of AT-GTX-501.
Sponsor: Emily de los Reyes • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Bacteria cocktail aims to boost cancer immunotherapy
Disease control CompletedThis study evaluated the safety and efficacy of VE800 in combination with nivolumab in patients with selected types of advanced or metastatic cancer
Phase: PHASE1, PHASE2 • Sponsor: Vedanta Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Poop pills may prevent dangerous side effects of cancer immunotherapy
Disease control OngoingCancer immunotherapy has been largely adopted in oncology patient management in the last decade. The deep and long responses to immunotherapy have accelerated the approval of these drugs across multiple disease sites. However, these agents can also be toxic to patients, meaning, …
Phase: PHASE1 • Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's • Aim: Disease control
Last updated Jun 26, 2026 17:19 UTC
-
New hope for kids with severe psoriasis: drug trial underway
Disease control OngoingThe purpose of the study is to evaluate the pharmacokinetic (PK) of certolizumab pegol (CZP) in study participants aged 6 to 17 years with moderate to severe chronic plaque psoriasis (PSO) in order to support extrapolation of efficacy.
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New study aims to predict dangerous side effects of cancer immunotherapy
Knowledge-focused Recruiting nowImmune checkpoint inhibitors (ICI) are among the most promising approaches to fighting cancer. However, a substantial percentage of patients experience off-target adverse effects in the form of mild to severe inflammation in different organs, commonly called immune-related advers…
Sponsor: Sir Mortimer B. Davis - Jewish General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Brain Radio' trial hopes to crack code of depression treatment
Disease control OngoingOf the estimated 30 million Americans who suffer from Major Depressive Disorder, approximately 10% are considered treatment resistant. Deep brain stimulation (DBS) to a region of the brain called the subcallosal cingulate (SCC) is an emerging strategy for treatment resistant depr…
Phase: NA • Sponsor: Helen Mayberg, MD • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New combo therapy shows promise for tough lung cancers
Disease control CompletedThe purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) in combination with boserolimab (MK-5890), MK-4830, MK-0482 in participants with advanced squamous or non-squamous NSCLC that have been previously treated with anti-PD-L1 therapy. This stud…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Scientists probe Ketamine's Fast-Acting depression relief in brain receptor study
Knowledge-focused Recruiting nowBackground: Most drugs that treat mood disorders take a long time to work. Ketamine works within hours. A dose can last for a week or more. Certain receptors in the brain might help ketamine work. A drug that blocks these receptors might affect how it works. Objective: To see …
Phase: PHASE1 • Sponsor: National Institute of Mental Health (NIMH) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New hip cup design aims to stop common complication in elderly fracture patients
Disease control CompletedOur aim is to develop a strategy that reduces the risk of dislocations after total hip arthroplasty surgery performed due to femoral neck fracture. We therefore perform a register-nested, pragmatic, randomized controlled trial to investigate the safety and efficacy of dual mobili…
Phase: NA • Sponsor: Uppsala University • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Cancer drug zanubrutinib tested for Long-Term safety in 955 patients
Disease control OngoingThe purpose of this study is to evaluate the long-term safety of zanubrutinib regimens in participants with B-cell malignancies who participated in a BeiGene parent study for zanubrutinib.
Phase: PHASE3 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New drug targets rare gene mutations in advanced cancers
Disease control CompletedThis phase II trial studies how well infigratinib works in treating solid tumors that have spread to other places in the body (advanced or metastatic) in patients with FGFR gene mutations such as FGFR1-3 gene fusions or other FGFR genetic alterations. Mutations are any changes in…
Phase: PHASE2 • Sponsor: Sameek Roychowdhury • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Saliva test could personalize care for Opioid-Affected newborns
Knowledge-focused Recruiting nowInfants with neonatal abstinence syndrome (NAS) experience prolonged hospital stays and poor neurodevelopmental outcomes, in-part because of the lack of accurate, individualized, biologic assessments available to manage this increasingly common medical condition. The proposed stu…
Sponsor: Milton S. Hershey Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC